At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 213 enrolled
Drug / intervention
LEO 80185 gel +1 moredrug
Likely dose
LEO 80185 gel 52.2 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 80185 gel and Dovobet ® ointment for Psoriasis Vulgaris. Completed, enrolled 213 participants across 1 site.
Detailed Summary
To compare the efficacy and safety of LEO 80185 gel with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesJapan
CollaboratorsCMIC Co, Ltd. Japan
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionJun 2016
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.4 years ago
Interventions
LEO 80185 geldrug
calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Dovobet ® ointmentdrug
calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions